Suppr超能文献

每周给予低剂量重组 VII 因子预防治疗 Glanzmann 血小板无力症。

Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia.

机构信息

Hematology Division, Osmangazi University Medical School, Meşelik Campus, Eskişehir, Turkey.

出版信息

Blood Coagul Fibrinolysis. 2021 Jul 1;32(5):349-351. doi: 10.1097/MBC.0000000000001026.

Abstract

Glanzmann thrombasthenia is an inherited disease causing bleeding episodes due to platelet dysfunction. The standard treatment for moderate-severe bleeding is platelet transfusion. Recombinant factor VIIa (rFVIIa) is successfully used in bleeding episodes and invasive procedures. Here, we present a patient with Glanzmann thrombasthenia, whose bleeding episodes could only be controlled by rFVIIa. The patient is a 28 years old male, who has had frequent bleeding episodes unresponsive to local hemostatic agents and tranexamic acid and had an anaphylactoid reaction to platelet transfusion. We started the patient on a low-dose (20 μg/kg) rFVIIa once a week. The patient has no spontaneous bleeding since then. This is the first case report of a Glanzmann thrombasthenia patient on routine prophylaxis with low-dose rFVIIa.

摘要

血管性血友病是一种遗传性疾病,由于血小板功能障碍导致出血发作。血小板输注是中重度出血的标准治疗方法。重组因子 VIIa(rFVIIa)在出血发作和侵入性操作中成功应用。在此,我们介绍一名血管性血友病患者,其出血发作只能用 rFVIIa 控制。患者为 28 岁男性,经常出血发作,对局部止血剂和氨甲环酸无反应,并对血小板输注发生过敏反应。我们开始每周给患者使用低剂量(20μg/kg)rFVIIa。从那时起,患者没有自发性出血。这是首例常规低剂量 rFVIIa 预防血管性血友病患者出血的病例报告。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验